Ivonescimab is a first-in-class, investigational bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor.
ANOTHER REMAINS ON THE RUN TONIGHT IN ROCKINGHAM COUNTY. MISSING PAPERWORK COULD PUT HIGH SCHOOL ATHLETE ELIGIBILITY AT RISK. WXII 12 SARAH SOWERS SPOKE WITH A TRIAD SCHOOL SUPERINTENDENT ABOUT THE ...
Peer review is a crucial process in science, but women's research articles spend 7-14 percent longer under review than those ...
AM Best has placed under review with negative implications the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a+” (Excellent) of ...
AM Best has revised the implications of the under review status to negative from developing for the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb+” (Good) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results